IL276661B2 - Immunogenic preparation containing staphylococcal antigens - Google Patents

Immunogenic preparation containing staphylococcal antigens

Info

Publication number
IL276661B2
IL276661B2 IL276661A IL27666120A IL276661B2 IL 276661 B2 IL276661 B2 IL 276661B2 IL 276661 A IL276661 A IL 276661A IL 27666120 A IL27666120 A IL 27666120A IL 276661 B2 IL276661 B2 IL 276661B2
Authority
IL
Israel
Prior art keywords
amino acid
seq
immunogenic composition
composition according
acid sequence
Prior art date
Application number
IL276661A
Other languages
English (en)
Hebrew (he)
Other versions
IL276661A (en
IL276661B1 (en
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of IL276661A publication Critical patent/IL276661A/en
Publication of IL276661B1 publication Critical patent/IL276661B1/en
Publication of IL276661B2 publication Critical patent/IL276661B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL276661A 2018-02-13 2019-02-12 Immunogenic preparation containing staphylococcal antigens IL276661B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens

Publications (3)

Publication Number Publication Date
IL276661A IL276661A (en) 2020-09-30
IL276661B1 IL276661B1 (en) 2023-04-01
IL276661B2 true IL276661B2 (en) 2023-08-01

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276661A IL276661B2 (en) 2018-02-13 2019-02-12 Immunogenic preparation containing staphylococcal antigens

Country Status (15)

Country Link
US (2) US11426455B2 (https=)
EP (1) EP3752183A1 (https=)
JP (1) JP2021514387A (https=)
KR (1) KR20200121825A (https=)
CN (1) CN112153980A (https=)
AR (1) AR114627A1 (https=)
AU (1) AU2019221496B2 (https=)
BR (1) BR112020016373A2 (https=)
CA (1) CA3090609A1 (https=)
EA (1) EA202091690A1 (https=)
GB (1) GB201802339D0 (https=)
IL (1) IL276661B2 (https=)
MX (1) MX2020008454A (https=)
SG (1) SG11202007676RA (https=)
WO (1) WO2019158537A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
JP7423133B2 (ja) 2020-09-21 2024-01-29 エルジー エナジー ソリューション リミテッド リチウム二次電池の活性化方法及びリチウム二次電池

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
WO2012003474A2 (en) * 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
SG188102A1 (en) * 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2654784B1 (en) 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US10195262B2 (en) 2013-12-04 2019-02-05 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
WO2012003474A2 (en) * 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants

Also Published As

Publication number Publication date
US11426455B2 (en) 2022-08-30
EA202091690A1 (ru) 2020-11-27
US20230052495A1 (en) 2023-02-16
WO2019158537A1 (en) 2019-08-22
CN112153980A (zh) 2020-12-29
KR20200121825A (ko) 2020-10-26
EP3752183A1 (en) 2020-12-23
US20210023192A1 (en) 2021-01-28
MX2020008454A (es) 2021-03-25
AR114627A1 (es) 2020-09-30
CA3090609A1 (en) 2019-08-22
AU2019221496B2 (en) 2022-12-08
AU2019221496A1 (en) 2020-08-27
BR112020016373A2 (pt) 2020-12-15
GB201802339D0 (en) 2018-03-28
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
SG11202007676RA (en) 2020-09-29
JP2021514387A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
JP2021514387A5 (https=)
Kim et al. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1–KLH and GD3–KLH conjugates
ES2276476T3 (es) Vacunas de emulsion de aceite en agua contra la hepatitis b.
CA2190344C (en) Quillaja saponin adjuvant and vaccine formulation containing same
EP2026841B1 (en) Conjugation process for pnag and a carrier protein
HRP20190711T1 (hr) Imunogeni pripravak
US9775898B2 (en) Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
HRP20120136T1 (hr) Imunogeni pripravak koji sadrži adjuvans
HU229968B1 (hu) Sztreptokokkusz oltóanyag
AR009958A1 (es) Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas.
HUP0300099A2 (en) Vaccine for the treatment of artherosclerosis
EA000839B1 (ru) Липосомальная вакцинная композиция, применение липосомальной вакцинной композиции и способ лечения млекопитающего
AU719084B2 (en) Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
BRPI0312472B8 (pt) composição compreendendo dois complexos iscom diferentes
BR0107679A (pt) Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
JP2004538330A (ja) 免疫応答増強剤
US10159729B2 (en) Antigen and method for production thereof
CN104093418A (zh) 金黄色葡萄球菌抗原的含佐剂制剂
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
JP2017511327A5 (https=)
JP2017511324A5 (https=)
JP2015529677A5 (https=)
RU2015106742A (ru) Композиции, содержащие химерные молекулы ospa и способы их применения